aluates Reports

$ 0.0

Automative

Global PDGFRα/β Multikinase Antagonists Market Research Report 2026

Published Date: 2026-03-05

Report Code: QYRE-Auto-9X20106

Global PDGFRα β Multikinase Antagonists Market Outlook In Depth Analysis Forecast to 2031

BUY CHAPTERS

Global PDGFRα/β Multikinase Antagonists Market Research Report 2026

Code: QYRE-Auto-9X20106

Report

2026-03-05

Pages:101

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Takeda

Bayer

Bristol–Myers Squibb

Il-Yang Pharmaceutical

PDGFRα/β Multikinase Antagonists Market Size

The global PDGFRα/β Multikinase Antagonists market was valued at US$ 2639 million in 2025 and is anticipated to reach US$ 4264 million by 2032, at a CAGR of 7.2% from 2026 to 2032.

PDGFRα/β Multikinase Antagonists Market

The FDA has approved more than 10 PDGFR multikinase antagonists for the treatment of various tumor diseases and pulmonary fibrosis. Recombinant PDGF is used to help treat chronic ulcers, orthopedic surgery and periodontal disease to stimulate bone regeneration and repair. When PDGF is used alone or in combination with other growth factors to stimulate soft and hard tissue healing.

The North American market for PDGFRα/β Multikinase Antagonists is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

The Asia-Pacific market for PDGFRα/β Multikinase Antagonists is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

The global market for PDGFRα/β Multikinase Antagonists in Hospitals is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.

Major global companies of PDGFRα/β Multikinase Antagonists include Novartis, Eli Lilly, Eisai, Pfizer, GSK, Boehringer Ingelheim, Il-Yang Pharmaceutical, Takeda, Bayer, Bristol-Myers Squibb, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.

This report delivers a comprehensive overview of the global PDGFRα/β Multikinase Antagonists market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding PDGFRα/β Multikinase Antagonists. The PDGFRα/β Multikinase Antagonists market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global PDGFRα/β Multikinase Antagonists market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist PDGFRα/β Multikinase Antagonists manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of PDGFRα/β Multikinase Antagonists Market Report

Report Metric	Details
Report Name	PDGFRα/β Multikinase Antagonists Market
Accounted market size in 2025	US$ 2639 million
Forecasted market size in 2032	US$ 4264 million
CAGR	7.2%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Type	Capsules Tablets Others
Segment by Application	Hospitals Clinics
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Novartis, Eli Lilly, Eisai, Pfizer, GSK, Boehringer Ingelheim, Il-Yang Pharmaceutical, Takeda, Bayer, Bristol-Myers Squibb
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for PDGFRα/β Multikinase Antagonists companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.

FAQ for this report

How fast is PDGFRα/β Multikinase Antagonists Market growing?

Ans: The PDGFRα/β Multikinase Antagonists Market witnessing a CAGR of 7.2% during the forecast period 2026-2032.

What is the PDGFRα/β Multikinase Antagonists Market size in 2032?

Ans: The PDGFRα/β Multikinase Antagonists Market size in 2032 will be US$ 4264 million.

Who are the main players in the PDGFRα/β Multikinase Antagonists Market report?

Ans: The main players in the PDGFRα/β Multikinase Antagonists Market are Novartis, Eli Lilly, Eisai, Pfizer, GSK, Boehringer Ingelheim, Il-Yang Pharmaceutical, Takeda, Bayer, Bristol-Myers Squibb

What are the Application segmentation covered in the PDGFRα/β Multikinase Antagonists Market report?

Ans: The Applications covered in the PDGFRα/β Multikinase Antagonists Market report are Hospitals, Clinics

What are the Type segmentation covered in the PDGFRα/β Multikinase Antagonists Market report?

Ans: The Types covered in the PDGFRα/β Multikinase Antagonists Market report are Capsules, Tablets, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global PDGFRα/β Multikinase Antagonists Market Size Growth Rate by Type: 2021 vs 2025 vs 2032

1.2.2 Capsules

1.2.3 Tablets

1.2.4 Others

1.3 Market by Application

1.3.1 Global PDGFRα/β Multikinase Antagonists Market Growth by Application: 2021 vs 2025 vs 2032

1.3.2 Hospitals

1.3.3 Clinics

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global PDGFRα/β Multikinase Antagonists Market Perspective (2021–2032)

2.2 Global PDGFRα/β Multikinase Antagonists Growth Trends by Region

2.2.1 Global PDGFRα/β Multikinase Antagonists Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 PDGFRα/β Multikinase Antagonists Historic Market Size by Region (2021–2026)

2.2.3 PDGFRα/β Multikinase Antagonists Forecasted Market Size by Region (2027–2032)

2.3 PDGFRα/β Multikinase Antagonists Market Dynamics

2.3.1 PDGFRα/β Multikinase Antagonists Industry Trends

2.3.2 PDGFRα/β Multikinase Antagonists Market Drivers

2.3.3 PDGFRα/β Multikinase Antagonists Market Challenges

2.3.4 PDGFRα/β Multikinase Antagonists Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top PDGFRα/β Multikinase Antagonists Players by Revenue

3.1.1 Global Top PDGFRα/β Multikinase Antagonists Players by Revenue (2021–2026)

3.1.2 Global PDGFRα/β Multikinase Antagonists Revenue Market Share by Players (2021–2026)

3.2 Global Top PDGFRα/β Multikinase Antagonists Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by PDGFRα/β Multikinase Antagonists Revenue

3.4 Global PDGFRα/β Multikinase Antagonists Market Concentration Ratio

3.4.1 Global PDGFRα/β Multikinase Antagonists Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by PDGFRα/β Multikinase Antagonists Revenue in 2025

3.5 Global Key Players of PDGFRα/β Multikinase Antagonists Head Offices and Areas Served

3.6 Global Key Players of PDGFRα/β Multikinase Antagonists, Products and Applications

3.7 Global Key Players of PDGFRα/β Multikinase Antagonists, Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4 PDGFRα/β Multikinase Antagonists Breakdown Data by Type

4.1 Global PDGFRα/β Multikinase Antagonists Historic Market Size by Type (2021–2026)

4.2 Global PDGFRα/β Multikinase Antagonists Forecasted Market Size by Type (2027–2032)

5 PDGFRα/β Multikinase Antagonists Breakdown Data by Application

5.1 Global PDGFRα/β Multikinase Antagonists Historic Market Size by Application (2021–2026)

5.2 Global PDGFRα/β Multikinase Antagonists Forecasted Market Size by Application (2027–2032)

6 North America

6.1 North America PDGFRα/β Multikinase Antagonists Market Size (2021–2032)

6.2 North America PDGFRα/β Multikinase Antagonists Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America PDGFRα/β Multikinase Antagonists Market Size by Country (2021–2026)

6.4 North America PDGFRα/β Multikinase Antagonists Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe PDGFRα/β Multikinase Antagonists Market Size (2021–2032)

7.2 Europe PDGFRα/β Multikinase Antagonists Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe PDGFRα/β Multikinase Antagonists Market Size by Country (2021–2026)

7.4 Europe PDGFRα/β Multikinase Antagonists Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific PDGFRα/β Multikinase Antagonists Market Size (2021–2032)

8.2 Asia-Pacific PDGFRα/β Multikinase Antagonists Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific PDGFRα/β Multikinase Antagonists Market Size by Region (2021–2026)

8.4 Asia-Pacific PDGFRα/β Multikinase Antagonists Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America PDGFRα/β Multikinase Antagonists Market Size (2021–2032)

9.2 Latin America PDGFRα/β Multikinase Antagonists Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America PDGFRα/β Multikinase Antagonists Market Size by Country (2021–2026)

9.4 Latin America PDGFRα/β Multikinase Antagonists Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa PDGFRα/β Multikinase Antagonists Market Size (2021–2032)

10.2 Middle East & Africa PDGFRα/β Multikinase Antagonists Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa PDGFRα/β Multikinase Antagonists Market Size by Country (2021–2026)

10.4 Middle East & Africa PDGFRα/β Multikinase Antagonists Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Novartis

11.1.1 Novartis Company Details

11.1.2 Novartis Business Overview

11.1.3 Novartis PDGFRα/β Multikinase Antagonists Introduction

11.1.4 Novartis Revenue in PDGFRα/β Multikinase Antagonists Business (2021–2026)

11.1.5 Novartis Recent Development

11.2 Eli Lilly

11.2.1 Eli Lilly Company Details

11.2.2 Eli Lilly Business Overview

11.2.3 Eli Lilly PDGFRα/β Multikinase Antagonists Introduction

11.2.4 Eli Lilly Revenue in PDGFRα/β Multikinase Antagonists Business (2021–2026)

11.2.5 Eli Lilly Recent Development

11.3 Eisai

11.3.1 Eisai Company Details

11.3.2 Eisai Business Overview

11.3.3 Eisai PDGFRα/β Multikinase Antagonists Introduction

11.3.4 Eisai Revenue in PDGFRα/β Multikinase Antagonists Business (2021–2026)

11.3.5 Eisai Recent Development

11.4 Pfizer

11.4.1 Pfizer Company Details

11.4.2 Pfizer Business Overview

11.4.3 Pfizer PDGFRα/β Multikinase Antagonists Introduction

11.4.4 Pfizer Revenue in PDGFRα/β Multikinase Antagonists Business (2021–2026)

11.4.5 Pfizer Recent Development

11.5 GSK

11.5.1 GSK Company Details

11.5.2 GSK Business Overview

11.5.3 GSK PDGFRα/β Multikinase Antagonists Introduction

11.5.4 GSK Revenue in PDGFRα/β Multikinase Antagonists Business (2021–2026)

11.5.5 GSK Recent Development

11.6 Boehringer Ingelheim

11.6.1 Boehringer Ingelheim Company Details

11.6.2 Boehringer Ingelheim Business Overview

11.6.3 Boehringer Ingelheim PDGFRα/β Multikinase Antagonists Introduction

11.6.4 Boehringer Ingelheim Revenue in PDGFRα/β Multikinase Antagonists Business (2021–2026)

11.6.5 Boehringer Ingelheim Recent Development

11.7 Il-Yang Pharmaceutical

11.7.1 Il-Yang Pharmaceutical Company Details

11.7.2 Il-Yang Pharmaceutical Business Overview

11.7.3 Il-Yang Pharmaceutical PDGFRα/β Multikinase Antagonists Introduction

11.7.4 Il-Yang Pharmaceutical Revenue in PDGFRα/β Multikinase Antagonists Business (2021–2026)

11.7.5 Il-Yang Pharmaceutical Recent Development

11.8 Takeda

11.8.1 Takeda Company Details

11.8.2 Takeda Business Overview

11.8.3 Takeda PDGFRα/β Multikinase Antagonists Introduction

11.8.4 Takeda Revenue in PDGFRα/β Multikinase Antagonists Business (2021–2026)

11.8.5 Takeda Recent Development

11.9 Bayer

11.9.1 Bayer Company Details

11.9.2 Bayer Business Overview

11.9.3 Bayer PDGFRα/β Multikinase Antagonists Introduction

11.9.4 Bayer Revenue in PDGFRα/β Multikinase Antagonists Business (2021–2026)

11.9.5 Bayer Recent Development

11.10 Bristol-Myers Squibb

11.10.1 Bristol-Myers Squibb Company Details

11.10.2 Bristol-Myers Squibb Business Overview

11.10.3 Bristol-Myers Squibb PDGFRα/β Multikinase Antagonists Introduction

11.10.4 Bristol-Myers Squibb Revenue in PDGFRα/β Multikinase Antagonists Business (2021–2026)

11.10.5 Bristol-Myers Squibb Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Takeda

Bayer

Bristol–Myers Squibb

Il-Yang Pharmaceutical

List of Tables

Table 1. Global PDGFRα/β Multikinase Antagonists Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

Table 2. Key Players of Capsules

Table 3. Key Players of Tablets

Table 4. Key Players of Others

Table 5. Global PDGFRα/β Multikinase Antagonists Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

Table 6. Global PDGFRα/β Multikinase Antagonists Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 7. Global PDGFRα/β Multikinase Antagonists Market Size by Region (US$ Million), 2021–2026

Table 8. Global PDGFRα/β Multikinase Antagonists Market Share by Region (2021–2026)

Table 9. Global PDGFRα/β Multikinase Antagonists Forecasted Market Size by Region (US$ Million), 2027–2032

Table 10. Global PDGFRα/β Multikinase Antagonists Market Share by Region (2027–2032)

Table 11. PDGFRα/β Multikinase Antagonists Market Trends

Table 12. PDGFRα/β Multikinase Antagonists Market Drivers

Table 13. PDGFRα/β Multikinase Antagonists Market Challenges

Table 14. PDGFRα/β Multikinase Antagonists Market Restraints

Table 15. Global PDGFRα/β Multikinase Antagonists Revenue by Players (US$ Million), 2021–2026

Table 16. Global PDGFRα/β Multikinase Antagonists Market Share by Players (2021–2026)

Table 17. Global Top PDGFRα/β Multikinase Antagonists Players by Tier (Tier 1, Tier 2, and Tier 3), based on PDGFRα/β Multikinase Antagonists Revenue, 2025

Table 18. Ranking of Global Top PDGFRα/β Multikinase Antagonists Companies by Revenue (US$ Million) in 2025

Table 19. Global 5 Largest Players Market Share by PDGFRα/β Multikinase Antagonists Revenue (CR5 and HHI), 2021–2026

Table 20. Global Key Players of PDGFRα/β Multikinase Antagonists, Headquarters and Area Served

Table 21. Global Key Players of PDGFRα/β Multikinase Antagonists, Products and Applications

Table 22. Global Key Players of PDGFRα/β Multikinase Antagonists, Date of General Availability (GA)

Table 23. Mergers and Acquisitions, Expansion Plans

Table 24. Global PDGFRα/β Multikinase Antagonists Market Size by Type (US$ Million), 2021–2026

Table 25. Global PDGFRα/β Multikinase Antagonists Revenue Market Share by Type (2021–2026)

Table 26. Global PDGFRα/β Multikinase Antagonists Forecasted Market Size by Type (US$ Million), 2027–2032

Table 27. Global PDGFRα/β Multikinase Antagonists Revenue Market Share by Type (2027–2032)

Table 28. Global PDGFRα/β Multikinase Antagonists Market Size by Application (US$ Million), 2021–2026

Table 29. Global PDGFRα/β Multikinase Antagonists Revenue Market Share by Application (2021–2026)

Table 30. Global PDGFRα/β Multikinase Antagonists Forecasted Market Size by Application (US$ Million), 2027–2032

Table 31. Global PDGFRα/β Multikinase Antagonists Revenue Market Share by Application (2027–2032)

Table 32. North America PDGFRα/β Multikinase Antagonists Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 33. North America PDGFRα/β Multikinase Antagonists Market Size by Country (US$ Million), 2021–2026

Table 34. North America PDGFRα/β Multikinase Antagonists Market Size by Country (US$ Million), 2027–2032

Table 35. Europe PDGFRα/β Multikinase Antagonists Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 36. Europe PDGFRα/β Multikinase Antagonists Market Size by Country (US$ Million), 2021–2026

Table 37. Europe PDGFRα/β Multikinase Antagonists Market Size by Country (US$ Million), 2027–2032

Table 38. Asia-Pacific PDGFRα/β Multikinase Antagonists Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

Table 39. Asia-Pacific PDGFRα/β Multikinase Antagonists Market Size by Region (US$ Million), 2021–2026

Table 40. Asia-Pacific PDGFRα/β Multikinase Antagonists Market Size by Region (US$ Million), 2027–2032

Table 41. Latin America PDGFRα/β Multikinase Antagonists Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 42. Latin America PDGFRα/β Multikinase Antagonists Market Size by Country (US$ Million), 2021–2026

Table 43. Latin America PDGFRα/β Multikinase Antagonists Market Size by Country (US$ Million), 2027–2032

Table 44. Middle East & Africa PDGFRα/β Multikinase Antagonists Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 45. Middle East & Africa PDGFRα/β Multikinase Antagonists Market Size by Country (US$ Million), 2021–2026

Table 46. Middle East & Africa PDGFRα/β Multikinase Antagonists Market Size by Country (US$ Million), 2027–2032

Table 47. Novartis Company Details

Table 48. Novartis Business Overview

Table 49. Novartis PDGFRα/β Multikinase Antagonists Product

Table 50. Novartis Revenue in PDGFRα/β Multikinase Antagonists Business (US$ Million), 2021–2026

Table 51. Novartis Recent Development

Table 52. Eli Lilly Company Details

Table 53. Eli Lilly Business Overview

Table 54. Eli Lilly PDGFRα/β Multikinase Antagonists Product

Table 55. Eli Lilly Revenue in PDGFRα/β Multikinase Antagonists Business (US$ Million), 2021–2026

Table 56. Eli Lilly Recent Development

Table 57. Eisai Company Details

Table 58. Eisai Business Overview

Table 59. Eisai PDGFRα/β Multikinase Antagonists Product

Table 60. Eisai Revenue in PDGFRα/β Multikinase Antagonists Business (US$ Million), 2021–2026

Table 61. Eisai Recent Development

Table 62. Pfizer Company Details

Table 63. Pfizer Business Overview

Table 64. Pfizer PDGFRα/β Multikinase Antagonists Product

Table 65. Pfizer Revenue in PDGFRα/β Multikinase Antagonists Business (US$ Million), 2021–2026

Table 66. Pfizer Recent Development

Table 67. GSK Company Details

Table 68. GSK Business Overview

Table 69. GSK PDGFRα/β Multikinase Antagonists Product

Table 70. GSK Revenue in PDGFRα/β Multikinase Antagonists Business (US$ Million), 2021–2026

Table 71. GSK Recent Development

Table 72. Boehringer Ingelheim Company Details

Table 73. Boehringer Ingelheim Business Overview

Table 74. Boehringer Ingelheim PDGFRα/β Multikinase Antagonists Product

Table 75. Boehringer Ingelheim Revenue in PDGFRα/β Multikinase Antagonists Business (US$ Million), 2021–2026

Table 76. Boehringer Ingelheim Recent Development

Table 77. Il-Yang Pharmaceutical Company Details

Table 78. Il-Yang Pharmaceutical Business Overview

Table 79. Il-Yang Pharmaceutical PDGFRα/β Multikinase Antagonists Product

Table 80. Il-Yang Pharmaceutical Revenue in PDGFRα/β Multikinase Antagonists Business (US$ Million), 2021–2026

Table 81. Il-Yang Pharmaceutical Recent Development

Table 82. Takeda Company Details

Table 83. Takeda Business Overview

Table 84. Takeda PDGFRα/β Multikinase Antagonists Product

Table 85. Takeda Revenue in PDGFRα/β Multikinase Antagonists Business (US$ Million), 2021–2026

Table 86. Takeda Recent Development

Table 87. Bayer Company Details

Table 88. Bayer Business Overview

Table 89. Bayer PDGFRα/β Multikinase Antagonists Product

Table 90. Bayer Revenue in PDGFRα/β Multikinase Antagonists Business (US$ Million), 2021–2026

Table 91. Bayer Recent Development

Table 92. Bristol-Myers Squibb Company Details

Table 93. Bristol-Myers Squibb Business Overview

Table 94. Bristol-Myers Squibb PDGFRα/β Multikinase Antagonists Product

Table 95. Bristol-Myers Squibb Revenue in PDGFRα/β Multikinase Antagonists Business (US$ Million), 2021–2026

Table 96. Bristol-Myers Squibb Recent Development

Table 97. Research Programs/Design for This Report

Table 98. Key Data Information from Secondary Sources

Table 99. Key Data Information from Primary Sources

Table 100. Authors List of This Report

List of Figures

Figure 1. PDGFRα/β Multikinase Antagonists Picture

Figure 2. Global PDGFRα/β Multikinase Antagonists Market Size Comparison by Type (US$ Million), 2021–2032

Figure 3. Global PDGFRα/β Multikinase Antagonists Market Share by Type: 2025 vs 2032

Figure 4. Capsules Features

Figure 5. Tablets Features

Figure 6. Others Features

Figure 7. Global PDGFRα/β Multikinase Antagonists Market Size by Application (US$ Million), 2021–2032

Figure 8. Global PDGFRα/β Multikinase Antagonists Market Share by Application: 2025 vs 2032

Figure 9. Hospitals Case Studies

Figure 10. Clinics Case Studies

Figure 11. PDGFRα/β Multikinase Antagonists Report Years Considered

Figure 12. Global PDGFRα/β Multikinase Antagonists Market Size (US$ Million), Year-over-Year: 2021–2032

Figure 13. Global PDGFRα/β Multikinase Antagonists Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 14. Global PDGFRα/β Multikinase Antagonists Market Share by Region: 2025 vs 2032

Figure 15. Global PDGFRα/β Multikinase Antagonists Market Share by Players in 2025

Figure 16. Global PDGFRα/β Multikinase Antagonists Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 17. The Top 10 and 5 Players Market Share by PDGFRα/β Multikinase Antagonists Revenue in 2025

Figure 18. North America PDGFRα/β Multikinase Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 19. North America PDGFRα/β Multikinase Antagonists Market Share by Country (2021–2032)

Figure 20. United States PDGFRα/β Multikinase Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 21. Canada PDGFRα/β Multikinase Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 22. Europe PDGFRα/β Multikinase Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 23. Europe PDGFRα/β Multikinase Antagonists Market Share by Country (2021–2032)

Figure 24. Germany PDGFRα/β Multikinase Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 25. France PDGFRα/β Multikinase Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 26. U.K. PDGFRα/β Multikinase Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 27. Italy PDGFRα/β Multikinase Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 28. Russia PDGFRα/β Multikinase Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 29. Ireland PDGFRα/β Multikinase Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 30. Asia-Pacific PDGFRα/β Multikinase Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 31. Asia-Pacific PDGFRα/β Multikinase Antagonists Market Share by Region (2021–2032)

Figure 32. China PDGFRα/β Multikinase Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 33. Japan PDGFRα/β Multikinase Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 34. South Korea PDGFRα/β Multikinase Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 35. Southeast Asia PDGFRα/β Multikinase Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 36. India PDGFRα/β Multikinase Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 37. Australia & New Zealand PDGFRα/β Multikinase Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 38. Latin America PDGFRα/β Multikinase Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 39. Latin America PDGFRα/β Multikinase Antagonists Market Share by Country (2021–2032)

Figure 40. Mexico PDGFRα/β Multikinase Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 41. Brazil PDGFRα/β Multikinase Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 42. Middle East & Africa PDGFRα/β Multikinase Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 43. Middle East & Africa PDGFRα/β Multikinase Antagonists Market Share by Country (2021–2032)

Figure 44. Israel PDGFRα/β Multikinase Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 45. Saudi Arabia PDGFRα/β Multikinase Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 46. UAE PDGFRα/β Multikinase Antagonists Market Size YoY Growth (US$ Million), 2021–2032

Figure 47. Novartis Revenue Growth Rate in PDGFRα/β Multikinase Antagonists Business (2021–2026)

Figure 48. Eli Lilly Revenue Growth Rate in PDGFRα/β Multikinase Antagonists Business (2021–2026)

Figure 49. Eisai Revenue Growth Rate in PDGFRα/β Multikinase Antagonists Business (2021–2026)

Figure 50. Pfizer Revenue Growth Rate in PDGFRα/β Multikinase Antagonists Business (2021–2026)

Figure 51. GSK Revenue Growth Rate in PDGFRα/β Multikinase Antagonists Business (2021–2026)

Figure 52. Boehringer Ingelheim Revenue Growth Rate in PDGFRα/β Multikinase Antagonists Business (2021–2026)

Figure 53. Il-Yang Pharmaceutical Revenue Growth Rate in PDGFRα/β Multikinase Antagonists Business (2021–2026)

Figure 54. Takeda Revenue Growth Rate in PDGFRα/β Multikinase Antagonists Business (2021–2026)

Figure 55. Bayer Revenue Growth Rate in PDGFRα/β Multikinase Antagonists Business (2021–2026)

Figure 56. Bristol-Myers Squibb Revenue Growth Rate in PDGFRα/β Multikinase Antagonists Business (2021–2026)

Figure 57. Bottom-up and Top-down Approaches for This Report

Figure 58. Data Triangulation

Figure 59. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions